M. Rouillon

Antitumor activity of S 16020-2 in two orthotopic models of lung cancer

L. Kraus-Berthier, A. Pierré, G. Atassi, 1997, Anti-cancer drugs.

In vivo antitumor activity of S 16020-2, a new olivacine derivative

E. Bisagni, L. Kraus-Berthier, M. Visalli, 1996, Cancer Chemotherapy and Pharmacology.

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

S. Apcher, Michael Ghosh, Camille Garcia, 2021, Communications Biology.

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

S. Apcher, Michael Ghosh, Camille Garcia, 2021, Communications biology.

Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3

P. Cascio, M. Khaled, A. Bachi, 2020, Oncoimmunology.

Experimental antitumour activity of S 16020-2 in a panel of human tumours.

L. Kraus-Berthier, G. Atassi, N. Guilbaud, 1997, European journal of cancer.

Splicing inhibition enhances the antitumor immune response through increased tumor antigen presentation and altered MHC-I immunopeptidome

C. Lobry, S. Apcher, Michael Ghosh, 2019, bioRxiv.